This message contains images. If you don't see images, click here to view. Click here to advertise in this news brief.   Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Jun. 27, 2012 Home   About The ATA   Join   Fellows' Corner   Gene expression assay successfully predicts benign disease in indeterminate thyroid nodules Endocrine Today    Share    A novel gene-expression classifier has been validated in reclassifying otherwise inconclusive results from thyroid biopsies as either benign or suspicious, according to data presented here at the Endocrine Society's 94th Meeting and Expo. The results were simultaneously published recently in the New England Journal of Medicine. "Thyroid nodules are very common; this year alone, in the U.S., nearly half a million diagnostic fine-needle aspirations will occur in the work-up of these nodules. Though many of them are benign, there's about a 5 percent to 15 percent risk that any thyroid nodule is cancerous. So evaluation is recommended, though the current diagnostic methods are both imprecise and, at times, inaccurate,” Erik Alexander, M.D., study author and physician-researcher in the division of endocrinology, diabetes and hypertension at Brigham and Women's Hospital, said during a press conference. More ATA advises thyroid collars not needed for mammography AuntMinnie.com    Share    Thyroid collars are not need for mammograms, according to new guidelines on minimizing radiation dose issued on June 13 by the American Thyroid Association. However, the association advised a number of other steps to minimize unnecessary exposure to radiation from medical and dental imaging procedures, such as the use of collars for dental X-rays. More TSH secreting tumors can be cured by long term octreotide treatment Clinical Thyroidology    Share    A measurable serum TSH level in the presence of frankly increased FT4 and FT3 is a very unusual situation. It should direct the diagnosis either toward thyroid hormone resistance or toward a pituitary adenoma secreting TSH (TSHoma). The main differential diagnosis of TSHomas is resistance to thyroid hormones (generalized, peripheral, or central). In TSHomas, the basal α-subunit has a tendency to be slightly increased but not in resistance to thyroid hormones. MRI and a TRH test that shows a minimal increase of serum TSH and of its α-subunit can distinguish the two conditions. Genetic screening of the beta T3 receptor will usually establish the diagnosis of thyroid hormone resistance, even though there are some cases that have not been elucidated genetically. The TSHoma described here can be considered a classical case on grounds of both biologic and imaging results. The patient has been treated for four years with octreotide with shrinkage of the tumor and return to normal thyroid function even after stopping treatment. More Advertisement Discover the Nature-Throid™ Difference Nature-Throid™ is a natural alternative to synthetic thyroid medications. Most synthetic thyroid drugs often contain only T4 hormone. Nature-Throid™ contains two thyroid hormones, T4 and T3.  Available by prescription in 13 strengths. more The AJCC TNM staging underestimates risk in young patients with more aggressive differentiated thyroid cancer Clinical Thyroidology    Share    The differentiated thyroid cancer staging system of the American Joint Committee on Cancer uses age for staging the patient. Patients less than age 45 with distant metastases are stage II, while patients age 45 or older with metastases are stage IV. Although age is linked to prognosis, it may be too optimistic to classify younger patients in this way. This study examined the effect of age and disease extent in the AJCC staging system on mortality using survival data from the Surveillance, Epidemiology, and End Results rogram from 1973 to 2005 in order to determine whether the risk stratification accurately portrayed outcomes of DTC for young patients. More India launches state-of-the-art system for monitoring salt iodization ICCIDD    Share    India was one of the first countries in Asia to implement salt iodization, with policies dating back to the early 1960s. While the country has made huge strides in increasing iodized salt production in recent years, progress has not always been steady. A lift on the ban of sale of non-iodized edible salt between 2000 and 2005 left iodized salt use suspended at 51 percent of households as per the National Family Health Survey 3. The ban's 2005 reinstatement - combined with heightened consumer awareness, effective monitoring, and improvements in iodization practices and packaging - helped to boost the use of iodized salt from 51 percent of households in 2005, to 71 percent by 2009 as per the UNICEF Coverage Evaluation Survey that year. More Advertisement Hyperparathyroidism charting in EMR can be easy With the right tools and workflow, charting an initial consultation for Hyperparathyroidism can be very easy and quick. You can also setup and manage reminders for yearly calcium levels automatically. Click here to see the video. MORE Natural form of parathyroid hormone decreased need for vitamin D, calcium in adults with hypoparathyroidism Endocrine Today    Share    Adults with hypoparathyroidism responded well to recombinant natural human parathyroid hormone, rhPTH. According to results presented here, the drug reduced the need for large amounts of calcium and vitamin D supplementation. "Many individuals with hypoparathyroidism are on very high amounts of calcium. Parathyroid hormone is the logical treatment for this disease, which is characterized by low or absent parathyroid hormone," John P. Bilezikian, M.D., professor of medicine and pharmacology at the College of Physicians and Surgeons at Columbia University, told Endocrine Today. More   ATA Thyroid Weekly News Briefs ATA does not develop, exert any editorial or other control, or guarantee the accuracy, completeness, efficacy, or timeliness, of the materials, information, advertising or promotional activities ("Content") in this publication. Inclusion of Content in this publication does not constitute or imply endorsement, agreement, recommendation, or favoring by ATA of such information or the entities mentioned or promoted herein. Use of any Content appearing or referenced in this publication or obtained from advertisers is voluntary, and reliance on it should only be undertaken after an independent review by qualified experts. ATA is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use of, reference to, reliance on, or performance pursuant to such Content. Colby Horton, Vice President of Publishing, 469.420.2601 Download media kit Julie Bernhard, Sr. Content Editor, 469.420.2647    Contribute news This edition of the ATA Thyroid Weekly News Briefs was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free! Recent issues June 27, 2012 June 20, 2012 June 13, 2012 June 6, 2012 7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063